These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 623381)

  • 21. Antiarrhythmic potency of N-acetylprocainamide.
    Elson J; Strong JM; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1975 Feb; 17(2):134-40. PubMed ID: 1122675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis for procainamide and N-acetyl procainamide in plasma or serum by high-performance liquid chromatography.
    Rocco RM; Abbott DC; Giese RW; Karger BL
    Clin Chem; 1977; 23(4):705-8. PubMed ID: 844165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function.
    Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM
    Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter: Fluorometric or gas-liquid chromatographic determination of procainamide?
    Frislid K; Bredesen JE; Lunde PK
    Clin Chem; 1975 Jul; 21(8):1180-2. PubMed ID: 1137928
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats.
    Watanabe J; Koyama I; Iwamoto K; Ozeki S
    J Pharm Pharmacol; 1987 Nov; 39(11):912-6. PubMed ID: 2448449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the TDX fluorescence polarization immunoassays for procainamide and n-acetylprocainamide.
    Sonsalla PK; Bridges RR; Jennison TA; Smith CM
    J Anal Toxicol; 1985; 9(4):152-5. PubMed ID: 2412001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective plasma concentration of N-acetylprocainamide in rats.
    Yacobi A; Krasula RW; Lai CM; Kamath BL
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):197-200. PubMed ID: 432435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration.
    Domoto DT; Brown WW; Bruggensmith P
    Ann Intern Med; 1987 Apr; 106(4):550-2. PubMed ID: 2435200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
    Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML
    Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic comparative study of procainamide and N-acetylprocainamide in anesthetized dogs: concentration-response relationships.
    Jaillon P; Winkle RA
    Circulation; 1979 Dec; 60(6):1385-94. PubMed ID: 91451
    [No Abstract]   [Full Text] [Related]  

  • 34. Simultaneous determination of procainamide and N-acetylprocainamide in plasma by high-performance liquid chromatography.
    Butterfield AG; Cooper JK; Midha KK
    J Pharm Sci; 1978 Jun; 67(6):839-42. PubMed ID: 660471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Procainamide pharmacokinetics in beagles: urinary pH dependency and comparison with n-acetylprocainamide.
    Baer DT; Barkus JC
    Res Commun Chem Pathol Pharmacol; 1977 Jun; 17(2):333-6. PubMed ID: 17895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide.
    Lahita R; Kluger J; Drayer DE; Koffler D; Reidenberg MM
    N Engl J Med; 1979 Dec; 301(25):1382-5. PubMed ID: 91972
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemoperfusion for treatment of N-acetylprocainamide intoxication.
    Braden GL; Fitzgibbons JP; Germain MJ; Ledewitz HM
    Ann Intern Med; 1986 Jul; 105(1):64-5. PubMed ID: 2424355
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.
    Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome.
    Kluger J; Drayer DE; Reidenberg MM; Lahita R
    Ann Intern Med; 1981 Jul; 95(1):18-23. PubMed ID: 6166229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphic acetylation procainamide in man.
    Reidenberg MM; Drayer DE; Levy M; Warner H
    Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.